• 제목/요약/키워드: kidney disease

검색결과 1,391건 처리시간 0.023초

단측에 발생한 사구체낭성신질환 1례 (A Case Report Unilaterally Involved Glomerulocystic Kidney Disease)

  • 오승진;육진원;김지홍;정현주;김명준;김병길
    • Childhood Kidney Diseases
    • /
    • 제3권2호
    • /
    • pp.221-226
    • /
    • 1999
  • Glomerulocystic kidney disease(GCKD) is a rare form of renal cystic disease defined histopathologically by containing dilated Bowman's space with variable atrophy of glomerular tufts, which may occur as sporadically or as familial cases and can be presented as a major component of heritable syndromes. It has not been recognized in Korean children but only one report of adult case has been reported having GCKD. We experienced a case of GCKD in a 10-year-10-month-old boy, who was admitted for hypertension. Abdominal ultrasonography and computed tomography revealed clustered numerous small cysts in left kidney and renal biopsy findings was consistent with the GCKD showing cystic dilatation of Bowman's space with intact glomerular structure.

  • PDF

Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study

  • Yoon, Chang-Yun;Lee, Misol;Kim, Seung Up;Lim, Hyunsun;Chang, Tae Ik;Kee, Youn Kyung;Han, Seung Gyu;Han, In Mee;Kwon, Young Eun;Park, Kyoung Sook;Lee, Mi Jung;Park, Jung Tak;Han, Seung Hyeok;Ahn, Sang Hoon;Kang, Shin-Wook;Yoo, Tae-Hyun
    • Kidney Research and Clinical Practice
    • /
    • 제36권1호
    • /
    • pp.48-57
    • /
    • 2017
  • Background: Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome in chronic kidney disease patients. Methods: CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean age, 57.5 years). Results: The median CAP value was 239 (202-274) dB/m. In 195 (41.9%) patients with metabolic syndrome, diabetes mellitus was more prevalent (105 [53.8%] vs. 71 [26.3%], P < 0.001), with significantly increased urine albumin-to-creatinine ratio (184 [38-706] vs. 56 [16-408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein levels (5.4 [1.4-28.2] vs. 1.7 [0.6-9.9] mg/L, P < 0.001), and CAP (248 [210-302] vs. 226 [196-259] dB/m, P < 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (${\beta}=0.742$, P < 0.001), triglyceride levels (${\beta}=2.034$, P < 0.001), estimated glomerular filtration rate (${\beta}=0.316$, P = 0.001), serum albumin (${\beta}=1.386$, P < 0.001), alanine aminotransferase (${\beta}=0.064$, P = 0.029), and total bilirubin (${\beta}=-0.881$, P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95% confidence interval, 1.009-1.183; P = 0.029) even after adjusting for multiple confounding factors. Conclusion: Increased CAP measured with transient elastography significantly correlated with and could predict increased metabolic syndrome risk in chronic kidney disease patients.

Kidney Organoid Derived from Human Pluripotent and Adult Stem Cells for Disease Modeling

  • Hyun Mi Kang
    • 한국발생생물학회지:발생과생식
    • /
    • 제27권2호
    • /
    • pp.57-65
    • /
    • 2023
  • Kidney disease affects a significant portion of the global population, yet effective therapies are lacking despite advancements in identifying genetic causes. This limitation can be attributed to the absence of adequate in vitro models that accurately mimic human kidney disease, hindering targeted therapeutic development. However, the emergence of human induced pluripotent stem cells (PSCs) and the development of organoids using them have opened up a way to model kidney development and disease in humans, as well as validate the effects of new drugs. To fully leverage their capabilities in these fields, it is crucial for kidney organoids to closely resemble the structure and functionality of adult human kidneys. In this review, we aim to discuss the potential of using human PSCs or adult kidney stem cell-derived kidney organoids to model genetic kidney disease and renal cancer.

Clinical Genetic Testing in Children with Kidney Disease

  • Kang, Eungu;Lee, Beom Hee
    • Childhood Kidney Diseases
    • /
    • 제25권1호
    • /
    • pp.14-21
    • /
    • 2021
  • Chronic kidney disease, the presence of structural and functional abnormalities in the kidneys, is associated with a lower quality of life and increased morbidity and mortality in children. Genetic etiologies account for a substantial proportion of pediatric chronic kidney disease. With recent advances in genetic testing techniques, an increasing number of genetic causes of kidney disease continue to be found. Genetic testing is recommended in children with steroid-resistant nephrotic syndrome, congenital malformations of the kidney and urinary tract, cystic disease, or kidney disease with extrarenal manifestations. Diagnostic yields differ according to the category of clinical diagnosis and the choice of test. Here, we review the characteristics of genetic testing modalities and the implications of genetic testing in clinical genetic diagnostics.

Kidney protective potential of lactoferrin: pharmacological insights and therapeutic advances

  • Zahan, Md. Sarwar;Ahmed, Kazi Ahsan;Moni, Akhi;Sinopoli, Alessandra;Ha, Hunjoo;Uddin, Md Jamal
    • The Korean Journal of Physiology and Pharmacology
    • /
    • 제26권1호
    • /
    • pp.1-13
    • /
    • 2022
  • Kidney disease is becoming a global public health issue. Acute kidney injury (AKI) and chronic kidney disease (CKD) have serious adverse health outcomes. However, there is no effective therapy to treat these diseases. Lactoferrin (LF), a multi-functional glycoprotein, is protective against various pathophysiological conditions in various disease models. LF shows protective effects against AKI and CKD. LF reduces markers related to inflammation, oxidative stress, apoptosis, and kidney fibrosis, and induces autophagy and mitochondrial biogenesis in the kidney. Although there are no clinical trials of LF to treat kidney disease, several clinical trials and studies on LF-based drug development are ongoing. In this review, we discussed the possible kidney protective mechanisms of LF, as well as the pharmacological and therapeutic advances. The evidence suggests that LF may become a potent pharmacological agent to treat kidney diseases.

상염색체 열성 다낭신 4례 (Four Cases of Autosomal Recessive Polycystic Kidney Disease)

  • 최웅규;이승철;박용원;이종국
    • Childhood Kidney Diseases
    • /
    • 제1권1호
    • /
    • pp.91-96
    • /
    • 1997
  • Polycystic kidney disease is defined as a heritable disorder with diffuse involvement of both kidneys without dysplasia other than cysts. The major clinical entities of autosomal recessive polycystic kidney disease and autosomal dominant polycystic kidney disease have a considerable overlap in clinical presentations and radiographic features in the pediatric population. We experienced three cases of autosomal recessive polycystic kidney disease of neonate who expired within 24 hours due to respiratory difficulty and the other case was detected by gross hematuria. So we report four cases with brief review of literatures.

  • PDF

Risk Factors for the Progression of Chronic Kidney Disease in Children

  • Ahn, Yo Han;Kang, Hee Gyung;Ha, Il-Soo
    • Childhood Kidney Diseases
    • /
    • 제25권1호
    • /
    • pp.1-7
    • /
    • 2021
  • Chronic kidney disease (CKD) in children is associated with various complications, including poor growth and development, mineral bone disorder, cardiovascular disease, kidney failure, and mortality. Slowing down the progression of CKD is important since CKD is often not curable. Prospective cohort studies have been conducted to understand the progression and outcomes of CKD in children, and these studies have identified non-modifiable and modifiable risk factors. Recognition of known risk factors and early intervention are important to delay the progression of kidney function decline in children.

양성 혈뇨를 동반한 Fraley증후군 1례 (A Case of Fraley's Syndrome with Benign Hematuria)

  • 최인경;김성아;김지홍;김병길;이재승;정현주;김명준;윤미진;이종두
    • Childhood Kidney Diseases
    • /
    • 제6권1호
    • /
    • pp.97-101
    • /
    • 2002
  • 저자들은 특이적인 증상없이 학교 신체검사중 우연히 발견된 현미경적 혈뇨를 주소로 내원하여 시행한 경정맥 신우조영술 및 복부비뇨기계 초음파 검사상 Fraley증후군 1례를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

  • PDF

Pediatric Kidney Transplantation

  • Lee, Yeon Hee;Kang, Hee Gyung
    • Childhood Kidney Diseases
    • /
    • 제25권1호
    • /
    • pp.8-13
    • /
    • 2021
  • Pediatric kidney transplantation is the best option since it can achieve near normal glomerular filtration rate, adequate fluid balance, and autonomic endocrine function of the kidney in end-stage kidney disease. However, pediatric kidney transplantation is difficult because children are developing and growing, management and complications of pediatric kidney transplantation are different from those of adults. This review covers the current status of pediatric kidney transplantation in Korea, key considerations that must be taken before kidney transplantation in children, and management strategy of immunosuppression and common complications.